Kerry A. Rogers, MD

Associate Professor
The Ohio State University

Dr. Kerry A. Rogers is an Associate Professor in the Division of Hematology at The Ohio State University and specializes in Chronic Lymphocytic Leukemia (CLL) and Hairy Cell Leukemia (HCL). She is a physician scientist working on chemotherapy-free combinations to improve the use of BTK inhibitors. In addition to caring for patients with CLL and HCL in clinic, she leads clinical trials studying novel regimens for CLL and hairy cell. Her other research interests include complications of targeted therapy for CLL, management of Richter’s syndrome, and autoimmune hemolytic anemia.

Poster(s):

• 1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia

• 1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.

• 1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study

• 1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity

• 2025 - Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib

• 2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database